Eli Lilly's new weight-loss drug crushes trials — ride the obesity drug wave

Verdict: a real obesity thesis on a watch-list, not a trade

The core thesis is genuinely strong: Lilly's June 2026 quarter showed revenue of $23.0B, up 16% sequentially, with operating cash flow of $10.7B (nearly double the prior quarter), a gross margin of 85.8%, and dividends growing 15.3% annually while shares outstanding shrink — the strongest point for the trade, per the June 8, 2026 MarketWatch coverage of the next-generation obesity trial. The strongest point against is that the entry rules have never fired across roughly 1,234 daily bars over five years, and today LLY sits $50.79 below the required $1,189.14 breakout level with trend strength at just 9.2 versus the 25 needed — this is a watch-list, not a trade. Insider filings for the period ended June 30, 2026 (a completed reporting period, roughly ten weeks old at retrieval) show net open-market selling of about $2.9M across 23 holders, and Lilly's own quarter showed net margin compressing to 30.9% from 37.4% and debt-to-equity rising 11.9% to 1.41. Novo, the coattails leg, is worse: FY2025 free cash flow fell 20% to $59B and return on equity dropped 25%, while its trend-strength reading of 0.6 is nowhere near the required 25. The verdict flips to actionable if LLY prints a daily close above $1,189.14 with trend strength rising through 20 and then 25 — and the October–November quarterly filing would confirm whether fundamentals are keeping pace.

Trade now: waiting on the breakout, not chasing it

**This is a watch-list setup, not an active signal.** LLY last closed at $1,138.35, which is $50.79 **below** the 10-day channel high of $1,189.14 that the entry requires a daily close above. The price condition is close; the trend-strength condition is not: ADX (14) sits at 9.2 and needs to rise above 20 and then 25, a distance the strategy flags as far. A fourth condition — a close above the first resistance level — also has to line up at the same time. None of these are met yet, so the correct move today is to do nothing and let the alerts fire. If all entry conditions align on the same daily close, the risk plan is mechanical: the position stops out at a 2.4% loss from entry or takes profit at a 4.8% gain, giving roughly 2-to-1 reward-to-risk on any triggered trade. Note that the exit-side logic is currently satisfied — price ($1,138.35) is $25.17 below the 10-day EMA of $1,163.52 — which is another way of saying LLY is in a pullback, not a confirmed uptrend. The same picture holds for NVO at $45.16 versus its 10-day channel high of $46.50, with ADX at just 0.6, about as far from a 25 threshold as it can get. One honest scope note: the rules did not trigger an entry anywhere in the evaluated history, so there are no realized trade statistics to lean on for this decision. The research author has asked for a bounded parameter review for exactly that reason; until a live entry triggers on the current rules, the practical plan is unchanged — set alerts at $1,189.14 on LLY (and $46.50 on NVO), watch ADX for confirmation, and wait.

Lilly's Obesity Franchise Is Backed by Real Earnings, Not Just a Trial Headline

The thesis — that Lilly has multiple blockbusters in obesity rather than one lucky drug, per the June 8, 2026 MarketWatch report on the late-stage trial of its next-generation weight-loss drug — has genuine fundamental support. Lilly's latest quarter (period ending June 30, 2026) shows revenue of $23.0B, up 16% from the prior quarter's $19.8B, with net income of $7.1B and a gross margin of 85.8%. Even the FY2025 Q4 snapshot put full-year revenue growth at 42.5% year over year, placing Lilly in the top quartile (roughly the 74th percentile) of Health Care peers on growth and the 79th percentile on gross margin. That is not a story stock; the fundamental machine is running hot. The cash generation also backs the bullish framing. Operating cash flow in the June 2026 quarter reached $10.7B, nearly double the prior quarter's $5.3B, and shares outstanding have steadily shrunk — from 1.15B in 2007 to 941 million by mid-2026 — meaning Lilly is compounding per-share value through buybacks while dividends grow 15.3% annually, with the trailing twelve-month payout at $6.69 per share and the most recent quarterly payment of $1.73. That combination of growth, buybacks, and rising dividends is consistent with the idea's claim of 'fundamental staying power beyond a single day's pop.' The competitive read is favorable too. Rival Novo Nordisk, the second symbol in this idea, grew revenue only 6.4% in FY2025 — around the 43rd percentile among Health Care peers — versus Lilly's 42.5%. While Novo remains enormously profitable (a 41.3% operating margin, 96th-percentile, and $59B of free cash flow in the 99th percentile), the growth gap is widening in Lilly's favor, exactly the market-share-capture story the thesis describes. As the idea notes, Novo could also ride renewed industry…

Scores

• Conviction score breakdown: 46
• Thesis support: 70
• Trade readiness: 35
• Risk quality: 45
• Trigger proximity: 20
• Fundamentals trend: 62

Watch items

• LLY — Daily close vs 10-day channel high
• LLY — ADX (14)
• LLY — Close vs 10-day EMA
• LLY — Insider open-market activity
• LLY — Quarterly net margin
• NVO — Daily close vs 10-day channel high
• NVO — ADX (14)
• LLY — Dividend ex-date